Press releases
Browse LEO Pharma’s global press releases intended for media.
Press releases issued by our local operating companies can be viewed on our market websites.
-
LEO Pharma announces annual results 2023
LEO Pharma announces annual results 2023 LEO Pharma delivers 10% revenue growth and returns to positive EBITDA Ballerup, February 29, 2024. – LEO Pharma delivers a solid operational…
-
LEO Pharma announces annual results 2022
LEO Pharma announces annual results 2022 Progressing on the financial turnaround, delivering a result in line with guidance, driven by solid growth in dermatology Today, LEO Pharma released…
-
Delivering a financial turnaround of LEO Pharma
Delivering a financial turnaround of LEO Pharma Ballerup – January 13: LEO Pharma is committed to being a global leader in medical dermatology by bringing innovative treatments to…
-
LEO Pharma appoints Paul Navarre new member of its Board of Directors
LEO Pharma appoints Paul Navarre new member of its Board of Directors Ballerup, Denmark, August 31, 2022 – LEO Pharma today announced the appointment of Paul Navarre as…
-
LEO Pharma appoints new Chief Financial Officer and Executive Vice President
LEO Pharma appoints new Chief Financial Officer and Executive Vice President Ballerup, Denmark, August 18, 2022 – LEO Pharma A/S today announced the appointment of Philip Eickhoff as…
-
LEO Pharma appoints new Executive Vice President of Global Product Supply
LEO Pharma appoints new Executive Vice President of Global Product Supply Ballerup, Denmark, August 03, 2022 – LEO Pharma A/S announced today the appointment of Sven Hauptmann as…
-
LEO Pharma appoints Elisabeth Svanberg new member of its Board of Directors
LEO Pharma appoints Elisabeth Svanberg new member of its Board of Directors Ballerup, June 28, 2022 – LEO Pharma today announced the appointment of Elisabeth Svanberg – MD,…
-
LEO Pharma strengthens its commercial organization
LEO Pharma strengthens its commercial organization Ballerup – June 2, 2022 – As part of LEO Pharma’s transformation towards becoming a global leader in medical dermatology, the company…
-
Emission reduction targets validated by the SBTi
LEO Pharma’s emission reduction targets validated by the Science Based Targets initiative The validation confirms that LEO Pharma’s climate targets to reduce green-house gas emissions are in line…
-
LEO Pharma announces annual results 2021
LEO Pharma announces annual results 2021 A year of investments and transformation of the global organization, progressing on strategy towards 2030 Growth in net salesNet sales grew 5%…
Media Inquiries
Head of Media
+4530502014
JEILK@leo-pharma.com
SVP, Head of Corporate Communications
+4529407016
ANMRN@leo-pharma.com
Media Manager
+4553748849
CHBUN@leo-pharma.com
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com
Our press releases are intended for the media
To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request. For updated information about clinical trials, please visit https://clinicaltrials.gov/.